A cancer blood test lives or dies on signal. For years, one of the quiet worries in the field has been noise — specifically, DNA shed by white blood cells that could blur the faint traces of a tumour circulating in plasma. A four-year Indian study now argues that this "noise" may be part of the signal.
Published in the Proceedings of the National Academy of Sciences (PNAS), the research draws on 43 hospitals across India and 1,480 participants. Its central observation is counterintuitive: in cancer patients, higher levels of circulating DNA were associated with stronger tumour signals and improved detection sensitivity.
Inside the Finding: When Immune DNA Rose, Tumour Signals Rose With It
The result strikes at a working assumption in liquid biopsy — the branch of diagnostics that looks for cancer in a blood draw rather than a tissue sample. Blood plasma carries cell-free DNA from many sources, and white blood cells are among the most prolific contributors.
Because of that, the worry was straightforward: if immune cells flood the sample with their own DNA, a tumour's small contribution could get lost in the background. The study's data points the other way, with the two signals moving together rather than competing.
Why the "Dilution" Fear Sat at the Centre of Liquid Biopsy
Every blood-based cancer test is, at its core, a problem of separation. A tumour sheds fragments of DNA carrying mutations or chemical markers; the same tube also contains fragments from healthy tissue and immune cells.
If white blood cell DNA simply added noise, sensitivity should fall as that background rises. The researchers report the opposite pattern — which, if it holds, changes what labs should do with that background: use it, rather than strip it out.
Four Years, 43 Hospitals, and a Question That Would Not Go Away
The scale of the study is notable for an Indian-led effort in this field. Data came from 43 hospitals over four years, with 1,480 participants enrolled in the evaluation.
That multi-site structure matters. Blood-based detection studies conducted at a single centre can carry hidden biases in sample handling, patient mix and timing of collection. Spreading collection across dozens of hospitals reduces some of that risk, though it cannot eliminate it.
Who This Reaches First: Patients Whose Cancer Is Still Silent
The people most affected by a finding like this are rarely the ones already in treatment. They are the ones with a persistent cough, an unexplained lump, a symptom their doctor cannot immediately place — the stage where a scan is inconclusive and a biopsy is invasive, expensive or hard to reach.
In a country where diagnostic access varies sharply between metros and smaller towns, a reliable blood test holds obvious appeal. It is also why claims in this area deserve more scrutiny than most.
What the PNAS Paper Does — and Does Not — Claim
According to the study, the evaluation of Strand Life Sciences' CancerSpot test produced an overall sensitivity of 72% and a false-positive rate of 1.4% across the 1,480 participants.
Those numbers should be read precisely. Sensitivity of 72% means the test identified roughly seven in ten cancers in the study group — and missed about three in ten. A 1.4% false-positive rate means that even a highly specific test will flag some people without cancer once it is applied to large, mostly healthy populations.
The Biology Behind the Signal Boost Is Still Being Worked Out
What the data shows is an association. What it does not yet settle is the mechanism — whether immune cells are actively responding to a tumour and shedding more DNA, whether both rise together for some other reason, or whether the relationship varies by cancer type and stage.
That distinction matters. An association strong enough to improve detection is useful even without a full explanation, but understanding the biology is what will tell researchers whether the effect travels beyond this cohort.
Confirmed, Reported, and Still Unclear
Confirmed: the study is peer-reviewed and published in PNAS; it covered 43 Indian hospitals and 1,480 participants over four years; it reports 72% sensitivity and 1.4% false-positive rate for the CancerSpot test; and it found circulating DNA levels tracking with stronger tumour signals.
Unclear from the available material: which cancer types were represented and in what proportions, how many early-stage versus late-stage cases were enrolled, whether the cohort included healthy controls or only symptomatic patients, and whether the company funded or co-authored the work. Each of these affects how the 72% figure should be interpreted.
Why CancerSpot Sits at the Centre of This Story
The test at the heart of the study belongs to Strand Life Sciences, an Indian genomics and diagnostics company. Its advantage here is not a mystery ingredient — it is data access: a 1,480-person, 43-hospital evaluation published in a peer-reviewed journal is a genuine asset that most diagnostic players in this space do not have.
But a moat in diagnostics is built from more than a paper. Regulatory approval, reimbursement, lab-to-lab reproducibility, turnaround time and clinician trust decide whether a test reaches patients. Publication is the start of that chain, not the end of it.
The Case for Caution Before Celebration
Three in ten cancers missed is not a small gap in a screening context. A test with 72% sensitivity can be genuinely useful as a triage tool — guiding who needs a scan or biopsy next — but it is not a rule-out test, and it should not be read as one.
There is also the question of independence. When the test being evaluated belongs to the company involved in the research, the strongest confirmation comes from groups with no commercial stake repeating the work in a different population. That has not yet been reported in the available material.
India's Long Bet on Blood-Based Cancer Screening
Cancer diagnosis in India often arrives late, and much of the reason is structural — distance to a tertiary centre, cost of imaging, fear of an invasive procedure. That gap is exactly where blood-based screening is being pitched hardest, by both Indian and global players.
The field has had a difficult run internationally, with several high-profile multicancer tests showing modest sensitivity for early-stage disease. A finding that improves signal rather than merely scaling sample size would be a more meaningful advance than another headline number.
What Patients and Doctors Should Take Away
For patients, the practical message is unglamorous: this is a research result, not a new standard of care. A negative blood test in a symptomatic person does not cancel the need for further investigation.
For clinicians, the value lies in study design. If white blood cell DNA carries information rather than noise, future assays may be built — and existing ones recalibrated — around that relationship, potentially lifting sensitivity without adding cost.
What the Next Study Needs to Prove
Replication is the first test. An independent team, ideally in a different country and with a cohort that includes a clear control group, would show whether the effect is biological or specific to this dataset.
After that, the questions turn practical: performance in stage I and II disease, behaviour in cancers that shed little DNA, and how many false positives a real screening programme would generate. Those answers typically take years, and not all of them will be flattering.
Our Take
This study is worth attention not because 72% is a breakthrough number, but because it questions a design assumption that has quietly shaped a decade of liquid biopsy work. If immune-cell DNA is informative rather than contaminating, the field has been discarding something useful.
The caution is equally important. A peer-reviewed paper, however large, is a single piece of evidence, and one co-produced with the test's own developer. The right posture is neither excitement nor dismissal — it is patience, with the numbers held to the standard the study itself has set.
Frequently Asked Questions
What exactly did the Indian study find about white blood cell DNA and cancer?
It found that in cancer patients, higher levels of circulating DNA were associated with stronger tumour signals and improved detection sensitivity. This challenges the older assumption that DNA from white blood cells dilutes or hides cancer signals in blood tests.
How accurate was the CancerSpot blood test in the study?
Strand Life Sciences' CancerSpot test showed an overall sensitivity of 72% and a false-positive rate of 1.4% across 1,480 participants. In practical terms, it detected about seven in ten cancers in the study group.
Does this mean a blood test can replace biopsy for cancer diagnosis?
No. A 72% sensitivity means a meaningful share of cancers would be missed, so a blood result cannot rule out cancer on its own. Such tests are better suited to triage — flagging who needs imaging or a biopsy next — and any decision belongs with a treating oncologist.
How reliable is this research for patients in India right now?
The study is peer-reviewed and published in PNAS with a large multi-hospital cohort, which adds credibility. But independent replication in other populations has not yet been reported in the available material, so it is a strong signal for researchers rather than a ready clinical pathway for patients today.